Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport

被引:1
作者
Atari, M. I. [1 ]
Chappell, M. J. [1 ]
Errington, R. J. [2 ]
Smith, P. J. [3 ]
Evans, N. D. [1 ]
机构
[1] Univ Warwick, Sch Engn, Coventry CV4 7AL, W Midlands, England
[2] Cardiff Univ, Univ Wales, Coll Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales
[3] Cardiff Univ, Univ Wales, Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales
基金
英国生物技术与生命科学研究理事会;
关键词
Efflux pump; Drug kinetics; Topotecan; Aldehyde dehydrogenase; Structural identifiability; Parameter estimation; DNA TOPOISOMERASE-I; MULTIDRUG-RESISTANCE; STEADY-STATE; TOPOTECAN; CELLS; IDENTIFIABILITY; CAMPTOTHECINS; BCRP/ABCG2; ABCG2;
D O I
10.1016/j.cmpb.2010.06.008
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the DNA target as well as the catalysis of the aldehyde dehydrogenase (ALDH) enzyme and the elimination of drug from the cytoplasm via the efflux pump. Verification of the proposed model is achieved using scanning-laser microscopy data from live human breast cancer cells. Before estimating the unknown model parameters from the experimental in vitro data it is essential to determine parameter uniqueness (or otherwise) from this imposed output structure. This is formally performed as a structural identifiability analysis, which demonstrates that all of the unknown model parameters are uniquely determined by the output structure corresponding to the experiment. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 50 条
  • [41] Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer
    Guo, Jianli
    Wang, Qingling
    Zhang, Yue
    Sun, Wenhui
    Zhang, Shuangzhe
    Li, Yachen
    Wang, Jingyun
    Bao, Yongming
    PHARMACOLOGICAL RESEARCH, 2019, 147
  • [42] Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells
    Li, Hong
    Jin, Hyo-Eon
    Kim, Wooyoung
    Han, Yong-Hae
    Kim, Dae-Duk
    Chung, Suk-Jae
    Shim, Chang-Koo
    PHARMACEUTICAL RESEARCH, 2008, 25 (11) : 2601 - 2612
  • [43] Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells
    Hong Li
    Hyo-Eon Jin
    Wooyoung Kim
    Yong-Hae Han
    Dae-Duk Kim
    Suk-Jae Chung
    Chang-Koo Shim
    Pharmaceutical Research, 2008, 25 : 2601 - 2612
  • [44] Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
    Nicolazzo, Joseph A.
    Katneni, Kasiram
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (02) : 130 - 147
  • [45] Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
    Das, Chandan Kanta
    Parekh, Aditya
    Parida, Pratap Kumar
    Bhutia, Sujit Kumar
    Mandal, Mahitosh
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2019, 1866 (06): : 1004 - 1018
  • [46] Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
    Tian, Ye
    Bian, Yicong
    Jiang, Yan
    Qian, Sainan
    Yu, Aiming
    Zeng, Su
    CURRENT DRUG METABOLISM, 2015, 16 (10) : 877 - 893
  • [47] Responsive Role of Nanomedicine in the Tumor Microenvironment and Cancer Drug Resistance
    Sa, Pratikshya
    Sahoo, Sanjeeb K.
    Dilnawaz, Fahima
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (29) : 3335 - 3355
  • [48] Inhibition of aldehyde dehydrogenase by furazolidone nanoemulsion to decrease cisplatin resistance in lung cancer cells
    Darooee, Mina
    Akbari, Vajihe
    Taheri, Azade
    THERAPEUTIC DELIVERY, 2021, 12 (08) : 611 - 625
  • [49] The Role of Exosomal microRNA in Cancer Drug Resistance
    Guo, Qiao-ru
    Wang, Hui
    Yan, Ying-da
    Liu, Yun
    Su, Chao-yue
    Chen, Hu-biao
    Yan, Yan-yan
    Adhikari, Rameshwar
    Wu, Qiang
    Zhang, Jian-ye
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
    Lagas, Jurjen S.
    van Waterschoot, Robert A. B.
    Sparidans, Rolf W.
    Wagenaar, Els
    Beijnen, Jos H.
    Schinkel, Alfred H.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (02) : 319 - 326